In this section you can read all the latest news about counterfeit and substandard medicines from around Europe and the world.
PRESS RELEASE: Nanomedicines and Nanosimilars — The EU urgently needs a Robust Centralised Regulatory Framework to Enhance Patient Safety
Nanomedicines are medicinal products of at least one dimension in the nanoscale ranges – from 1nm to 100nm. They enhance the way in which medicines
EVENT: Preventing Medication errors across European hospitals to protect patient safety: Launch of the White Paper on Medication Errors and Traceability – 22 March 2022 – 11:30 to 13:30 CET
The European Alliance for Access to Safe Medicines (EAASM) invites you to join its Parliament roundtable debate entitled “Preventing Medication errors across European hospitals to protect patient
Event summary of “Nanomedicines and nanosimilars: the medical need for a centralised EMA regulatory process” held as a live webinar on 30th November 2021 10.00-11.30
PRESS RELEASE: Nanomedicines and nanosimilars: the medical need for a centralised EMA regulatory process
Nanomedicines enhance the way that medicines target and reach areas of disease within the body, opening up new therapeutic options. They offer potential solutions for